Respiratory Syncytial Virus (RSV)

Sanofi Pasteur signed an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, on March 2, 2017, to develop and commercialize a monoclonal antibody--called MEDI8897--for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.

In addition, Sanofi Pasteur is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to further advance attenuated RSV candidate vaccines for the prevention of RSV disease in infants and young children.
According to the Centers for Disease Control and Prevention, RSV is the most common cause of lower respiratory tract infections in children younger than 1 year of age in the United States and worldwide*. There are no specific treatments for RSV and there is no vaccine. Current therapies are focused on alleviating the symptoms of the infection.

*https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6348a3.htm


Related article


Inoculation Innovation: Bringing New Technology to Vaccines

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK